Integris Medtech Files DRHP With SEBI for ₹925 Crore IPO

Integris Medtech Limited has taken a significant step toward its initial public offering by filing its Draft Red Herring Prospectus. The Indian medical devices company submitted the document to the Securities and Exchange Board of India on Thursday.

The proposed IPO aims to raise up to ₹9,250 million through a combination of fresh equity and an offer for sale. This move represents a major corporate development for the New Delhi-based company established in 2008.

IPO Structure and Shareholder Participation

The public offering comprises two distinct components that together create the ₹925 crore fundraising target. A fresh issue of shares will inject new capital directly into the company's operations.

Simultaneously, an Offer for Sale will facilitate the divestment of up to 21,674,531 equity shares by existing promoters. The selling shareholders include Evercure Holdings Pte. Ltd., Gurmit Singh Chugh, and Punita Sharma, who will collectively offer their stakes.

Utilisation of IPO Proceeds

The company has outlined specific allocation plans for the net proceeds from the fresh issue portion. A significant portion will be directed toward repaying or prepaying borrowings availed by its subsidiaries.

The beneficiary entities include Translumina Therapeutics, Transhealth, HaleMed Medical, CPC Diagnostics, and Chemopharm Group. Any remaining amount after debt repayment will be allocated for general corporate purposes. This strategic allocation aims to strengthen the company's financial position.

Financial Performance and Market Position

Integris Medtech demonstrated robust financial performance during fiscal year 2025. Revenue from operations grew 13.2% year-on-year to ₹19,024.66 million, showing sustained business expansion.

Profit after tax increased 10.9% to ₹1,178.44 million, reflecting healthy bottom-line growth. According to Frost & Sullivan analysis, the company ranks among India's top two MedTech companies by operating revenue. This market position underscores its competitive strength in the healthcare sector.

Corporate Background and Operations

The company has established itself as a significant player in India's medical technology landscape since its inception in 2008. Integris Medtech provides comprehensive medical devices and laboratory solutions across healthcare segments.

Its headquarters in New Delhi serves as the central hub for nationwide operations and strategic management. The company's diversified subsidiary structure supports its broad market presence across multiple therapeutic areas.

Industry Context and Future Prospects

The IPO emerges during a period of growing investor interest in India's healthcare and medical technology sectors. The company's strong financial performance positions it favorably for public market reception.

Proceeds from the offering will facilitate debt reduction across its subsidiary network, potentially improving profitability. The public listing will provide Integris Medtech with enhanced visibility and financial flexibility for future expansion.

Read More: India Sees Strong IPO Fund-Raising Activity

Conclusion

Integris Medtech's DRHP filing marks a pivotal moment in the company's corporate journey. The proposed IPO represents a strategic initiative to strengthen its financial foundation and support growth objectives.

Successful completion will provide the company with additional resources to enhance its competitive position in the MedTech industry. The public offering will also offer existing promoters partial exit opportunities while bringing new investors into the company's ownership structure.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.